ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1062

Sex-related differences in clinical presentation and patient-reported burden in chronic back pain: Are these findings specific to axSpA? Results from the SHERPAS Cohort

Diego Benavent1, Mar Tapia2, Daniel Bernabeu2, Victor Muley2, Manuel Juárez3, Alejandro Balsa4, Chamaida Plasencia-Rodríguez4 and Victoria Navarro-Compan5, 1Hospital Universitari de Bellvitge, Madrid, Spain, 2HU La Paz, Madrid, Spain, 3Rheumatology Unit, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, 4Hospital Universitario La Paz, Madrid, Spain, 5Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain

Meeting: ACR Convergence 2025

Keywords: Back pain, gender, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1055–1087) Healthcare Disparities in Rheumatology Posters

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Sex-related differences in axial spondyloarthritis (axSpA) have been described regarding clinical features, disease burden, and particularly patient-reported outcomes. These differences influence patient management, including diagnostic strategies and referral patterns. However, it remains unclear whether these sex-specific differences represent a distinct feature of axSpA or if similar patterns also occur in the broader population of patients with chronic back pain (CBP) without axSpA. The objective of this study is to assess sex differences in demographic and clinical features, including patient-reported disease activity and functional impairment, among young adults with CBP referred by non-rheumatology specialists.

Methods: A prospective, cross-sectional observational study was conducted between July 2021 and October 2023 as part of the “Strategy for a Hospital Early Referral in Patients with Axial Spondyloarthritis” (SHERPAS) Cohort. Adults aged 18–40 years with CBP ( >3 months duration) referred for spinal magnetic resonance imaging (MRI) by non-rheumatology specialists completed detailed questionnaires capturing demographic characteristics, lifestyle factors and patient-reported outcomes (PROs), including disease activity and functional impairment measured by BASDAI and BASFI. MRI imaging of the spine and sacroiliac joints (SIJ) were performed within two weeks, as well as a consultation with the rheumatologist. Diagnoses were based on expert clinical judgment considering imaging, clinical, and laboratory data. Only patients in whom a diagnosis of axSpA had been ruled out were included. Statistical comparisons by sex were conducted using appropriate parametric or non-parametric tests.

Results: Among 260 patients, 149 (57.3%) were female, and mean age was 34.6±5.6 years. While most demographic and clinical characteristics did not differ significantly by sex (Table 1), marked differences were observed in PROs. Female reported significantly higher overall BASDAI (4.9±2.5 vs 3.6±2.4; p< 0.001) and higher overall BASFI (3.7±2.7 vs 2.8±2.5; p=0.004) versus males. Concerning individual BASDAI items (Figure 1), female reported higher scores in fatigue (5.6 ± 3.1 vs 4.1 ± 2.9; p< 0.001), spinal pain (6.5 ± 3.0 vs 5.1 ± 3.2; p=0.001), peripheral pain (3.4 ± 3.4 vs 1.9 ± 2.7; p < 0.001), and general discomfort/enthesitis (5.2 ± 3.5 vs 3.3 ± 3.1; p < 0.001) than males. Female also had higher functional impairment in BASFI items, particularly showing greater difficulty reaching an object on a shelf (3.0 ± 3.4 vs 1.8 ± 2.8; p=0.002), rising from the floor (4.3 ± 3.7 vs 2.9 ± 3.3; p=0.002), standing for 10 minutes (5.1 ± 3.6 vs 3.7 ± 3.5; p=0.002), climbing 15 steps (3.5 ± 3.5 vs 2.1 ± 3.1; p=0.001) and turning the head over the shoulder (2.6 ± 3.3 vs 1.3 ± 2.4; p< 0.001).

Conclusion: Significant sex differences were observed in the clinical presentation of young adults with CBP, particularly in patient-reported disease activity and functional limitation scores. These findings suggest that sex-related disparities in disease burden are not specific to axSpA, highlighting the need for broader sex-sensitive strategies in the evaluation and management of all young patients with CBP.

Supporting image 1Table 1. Characteristics of patients in the SHERPAS cohort stratified by sex

Supporting image 2Figure 1. Items of BASDAI (a) and BASFI (b) stratified by sex


Disclosures: D. Benavent: AbbVie/Abbott, 2, 6, Eli Lilly, 6, Janssen, 6, Novartis, 5, 6, Pfizer, 6, Savana, 7, UCB, 2, 6; M. Tapia: None; D. Bernabeu: None; V. Muley: None; M. Juárez: Gebro Pharma, 6; A. Balsa: AbbVie/Abbott, 6, Eli Lilly, 6, Janssen, 6, Pfizer, 6, UCB, 6; C. Plasencia-Rodríguez: AbbVie/Abbott, 5, 6, Eli Lilly, 6, Novartis, 6, Pfizer, 5, 6, UCB, 6; V. Navarro-Compan: AbbVie, 2, 5, 6, Alfasigma, 2, Bristol Myers Squibb, 2, 5, 6, Fresenius Kabi, 2, 5, 6, Galapagos, 2, 5, 6, Janssen, 2, 5, 6, Lilly, 2, 5, 6, MoonLake, 2, 5, 6, MSD, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Roche, 2, 5, 6, UCB, 2, 5, 6.

To cite this abstract in AMA style:

Benavent D, Tapia M, Bernabeu D, Muley V, Juárez M, Balsa A, Plasencia-Rodríguez C, Navarro-Compan V. Sex-related differences in clinical presentation and patient-reported burden in chronic back pain: Are these findings specific to axSpA? Results from the SHERPAS Cohort [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/sex-related-differences-in-clinical-presentation-and-patient-reported-burden-in-chronic-back-pain-are-these-findings-specific-to-axspa-results-from-the-sherpas-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sex-related-differences-in-clinical-presentation-and-patient-reported-burden-in-chronic-back-pain-are-these-findings-specific-to-axspa-results-from-the-sherpas-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology